Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001009684	A pan-cancer cohort of 1031 patients resistant to systemic therapies or with no approved therapeutic options. It includes whole-exome sequencing of 571 tumor and matched-normal samples, and transcriptome sequencing of 947 tumor samples. Biopsies were taken at entry into precision medicine trials, often after diagnosed resistance. Comprehensive clinical information is available for all patients and include patient age at biospy, tumor primary site and histological subtype, biopsy site, treatments received prior to biopsy, blood assessment results at biopsy, metastatic sites at biopsy, and survival time from the biopsy date.	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000 Illumina NovaSeq 6000 NextSeq 500	2089

Publications	Citations
Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer. Pradat Y, Viot J, Yurchenko AA, Gunbin K, Cerbone L, Deloger M, Grisay G, Verlingue L, Scott V, Padioleau I, Panunzi L, Michiels S, Hollebecque A, Jules-Clément G, Mezquita L, Lainé A, Loriot Y, Besse B, Friboulet L, André F, Cournède PH, Gautheret D, Nikolaev SI. Cancer Discov 13: 2023 1116-1143	8